4Philipsom JD. British HerbalPharmacopoeia [M]. British Herbal Medicine Association Publucations. 1996 Forward.
5Indian Drug Manufacturere' s Association. Indian Herbal Pharmacopoeia [M]. VedamsBooks International. 1998 Volume 1.
6Natalie Lazarowych. Use of Fingerprinting and Marker Compounds for Identificationand Standardization of Botanical Drugs: Strategies for Applying Pharmceutical HPLCAnalysis to Herbal Products [J]. Drug Information Journal, 1998, 32: 497-512.
7Peter John Houghton. Establishing Identification Criteria for Botanicals [J]. DrugInformation Journal, 1998, 32: 461 - 469.
8FDA Guidance for Industry- Botanical Drug Products (Draft Guidance), Ⅷ, B, 2e;3e; August 2000.
9WHO. Guidelines for the Assessment of Herbal Medicines 1996.
7YUAN Hai-long1,ZHANG Tian-tian1,2,XIAO Xiao-he1 1.Institute of Chinese Materia Medica,302 Military Hospital,Beijing 100039,China 2.Pharmacy College,Chengdu University of Traditional Chinese Medicine,Chengdu 610075,China.Quality Control Approaches for Chinese Herbal Medicines[J].Chinese Herbal Medicines,2011,3(1):17-22. 被引量：2
7Julius S, Nesbitt SD, Egan BM, et al.Feasibility of treating prehypertension with an angiotensin-receptor blockor [J]. NEJM,2006,354:1685-1697.
8Julius S, NesbittSD, Egan BM,etal. TheTrial of PreventingH pertension (TROPHY) Study Investigators. Feasibility of treati prehypertension with an angiotensin-receptor blocker [J]. N Eng Med, 2006, 354: 1685-1697.
9Klocek M, Kawecka J K. Quality of life in patients with es- sential arterial hypertension. Part II : The effect of clinical factors [ J ] .Przegl Lek ,2003,60 (2) :101 - 106.
